ARTL
Price
$3.68
Change
-$0.15 (-3.92%)
Updated
Oct 2 closing price
Capitalization
2.36M
46 days until earnings call
Intraday BUY SELL Signals
FATE
Price
$2.32
Change
+$0.02 (+0.87%)
Updated
Oct 2 closing price
Capitalization
285.17M
27 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARTL vs FATE

ARTL vs FATE Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ARTL vs. FATE commentary
Oct 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARTL is a Hold and FATE is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
ARTL vs FATE: Fundamental Ratings
ARTL
FATE
OUTLOOK RATING
1..100
9845
VALUATION
overvalued / fair valued / undervalued
1..100
7
Undervalued
28
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
9638
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARTL's Valuation (7) in the null industry is in the same range as FATE (28) in the Biotechnology industry. This means that ARTL’s stock grew similarly to FATE’s over the last 12 months.

ARTL's Profit vs Risk Rating (100) in the null industry is in the same range as FATE (100) in the Biotechnology industry. This means that ARTL’s stock grew similarly to FATE’s over the last 12 months.

FATE's SMR Rating (98) in the Biotechnology industry is in the same range as ARTL (100) in the null industry. This means that FATE’s stock grew similarly to ARTL’s over the last 12 months.

FATE's Price Growth Rating (38) in the Biotechnology industry is somewhat better than the same rating for ARTL (96) in the null industry. This means that FATE’s stock grew somewhat faster than ARTL’s over the last 12 months.

FATE's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ARTL (100) in the null industry. This means that FATE’s stock grew similarly to ARTL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARTLFATE
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 10 days ago
77%
Bullish Trend 5 days ago
88%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
COMPARISON
Comparison
Oct 03, 2026
Stock price -- (ARTL: $3.83 vs. FATE: $2.30)
Brand notoriety: ARTL and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARTL: 15% vs. FATE: 48%
Market capitalization -- ARTL: $2.36M vs. FATE: $285.17M
ARTL [@Biotechnology] is valued at $2.36M. FATE’s [@Biotechnology] market capitalization is $285.17M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARTL’s FA Score shows that 1 FA rating(s) are green while FATE’s FA Score has 1 green FA rating(s).

  • ARTL’s FA Score: 1 green, 4 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, FATE is a better buy in the long-term than ARTL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARTL’s TA Score shows that 3 TA indicator(s) are bullish while FATE’s TA Score has 2 bullish TA indicator(s).

  • ARTL’s TA Score: 3 bullish, 6 bearish.
  • FATE’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, FATE is a better buy in the short-term than ARTL.

Price Growth

ARTL (@Biotechnology) experienced а -25.92% price change this week, while FATE (@Biotechnology) price change was -1.29% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.63%. For the same industry, the average monthly price growth was -14.35%, and the average quarterly price growth was -1.64%.

Reported Earning Dates

ARTL is expected to report earnings on Nov 17, 2026.

FATE is expected to report earnings on Oct 29, 2026.

Industries' Descriptions

@Biotechnology (-3.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ARTL
Daily Signal:
Gain/Loss:
FATE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
KLAG28.701.40
+5.14%
Leverage Shares 2x Long KLAC Daily ETF (KLAG)
VGIT56.64-0.02
-0.04%
Vanguard Intermediate-Term Treasury ETF (VGIT)
MPRO31.39-0.03
-0.10%
Monarch ProCap Index ETF (MPRO)
ENZL44.89-0.19
-0.41%
iShares MSCI New Zealand ETF (ENZL)
PML6.48-0.09
-1.37%
PIMCO Municipal Income FUND II

ARTL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARTL has been loosely correlated with PALI. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if ARTL jumps, then PALI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARTL
1D Price
Change %
ARTL100%
-5.20%
PALI - ARTL
34%
Loosely correlated
+5.93%
CRMD - ARTL
32%
Poorly correlated
-3.64%
FATE - ARTL
31%
Poorly correlated
-2.95%
LSTA - ARTL
29%
Poorly correlated
+3.47%
SPRO - ARTL
28%
Poorly correlated
+4.13%
More

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with NKTX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then NKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
-2.95%
NKTX - FATE
45%
Loosely correlated
-2.29%
VCYT - FATE
44%
Loosely correlated
-4.02%
PTN - FATE
41%
Loosely correlated
+2.14%
CYTK - FATE
39%
Loosely correlated
-0.44%
REPL - FATE
39%
Loosely correlated
+1.59%
More